Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
RUBY Part 1 All-Comers Efficacy Data
4-year Survival Outcomes in the dMMR/MSI-H Subpopulation of RUBY Part 1
The 4-year follow-up analysis demonstrated sustained long-term PFS benefit with JEMPERLI + CP vs placebo + CP*1
Descriptive analysis (not statistically powered) of dual primary endpoint: 4-year follow-up of PFS in the dMMR/MSI-H population (N=118)
Only 4 new progression events with an additional 2.5 years of follow-up from IA1, with median PFS not reached in the JEMPERLI + CP arm
Adapted from Powell et al, 2026.1
*Median expected follow-up, 55.6 months (range, 49.9–67.7).1
CI=confidence interval; CP=carboplatin + paclitaxel; dMMR=mismatch repair deficient; HR=hazard ratio; IA1=first interim analysis; mPFS=median progression-free survival; MSI-H=microsatellite instability-high; NE=not estimable; PFS=progression-free survival.
The 4-year follow-up analysis demonstrated sustained long-term OS benefit with JEMPERLI + CP vs placebo + CP*1
Descriptive analysis (not statistically powered) of dual primary endpoint: 4-year follow-up of OS in the
dMMR/MSI-H population (N=118)
Median OS not reached in the JEMPERLI + CP arm
Adapted from Powell et al, 2026.1
*Median expected follow-up, 55.6 months (range, 49.9–67.7).1
CI=confidence interval; CP=carboplatin + paclitaxel; dMMR=mismatch repair deficient; FUACT=follow-up anti-cancer treatment; HR=hazard ratio; IO=immunotherapy; mOS=median overall survival; MSI-H=microsatellite instability-high; NE=not estimable; OS=overall survival.
In the JEMPERLI + CP arm, patients who were progression-free at 2 years had >90% probability of remaining progression-free and alive at 4 years1
Conditional PFS in the dMMR/MSI-H population (n=53)1
| dMMR/MSI-H population | JEMPERLI + CP |
| 3-year progression-free probability from 1-year landmark | 88.6% (95% CI, 68.5–96.2) |
| 2-year progression-free probability from 2-year landmark | 91.7% (95% CI, 70.6–97.8) |
| 1-year progression-free probability from 3-year landmark | 91.7% (95% CI, 70.6–97.8) |
Adapted from Powell et al, 2026.1
In the JEMPERLI + CP arm patients who were alive at 1 and 2 years had >80% probability of remaining alive at 4 years1
Conditional OS in the dMMR/MSI-H population (n=53)1
| dMMR/MSI-H population | JEMPERLI + CP |
| 3-year survival probability from 1-year landmark | 84.0% (95% CI, 69.3–92.0) |
| 2-year survival probability from 2-year landmark | 88.0% (95% CI, 73.5–94.8) |
| 1-year survival probability from 3-year landmark | 94.7% (95% CI, 80.6–98.7) |
Adapted from Powell et al, 2026.1
Conditional survival is an alternative and dynamic estimate of survival, representing the probability that a patient remains free of progression and death (cPFS) or remains alive (cOS) for additional time from a specified time point.1
CI=confidence interval; cOS=conditional overall surivival; CP=carboplatin + paclitaxel; cPFS=conditional progression-free survival; dMMR=mismatch repair deficient; MSI-H=microsatellite instability-high; OS=overall survival; PFS=progression free survival.
RUBY Part 1 Trial Design: A phase 3, randomised, double-blind trial of patients with primary advanced or recurrent EC (N=494, all-comers) who were randomised 1:1 to JEMPERLI + CP or placebo + CP Q3W for 6 cycles, followed by JEMPERLI or placebo Q6W, respectively, until disease progression, unacceptable toxicity, or up to 3 years. Major efficacy endpoints were investigator-assessed PFS by RECIST v1.1 in the dMMR/MSI-H and all-comers populations, and OS in all-comers.2
dMMR=mismatch repair deficient; EC=endometrial cancer; MSI-H=microsatellite instability-high; Q3W=every 3 weeks; Q6W=every 6 weeks; RECIST v1.1=Response Evaluation Criteria in Solid Tumours v1.1.
Find Out More
JEMPERLI Is Indicated
- in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy.
- as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced EC that has progressed on or following prior treatment with a platinum-containing regimen.
References
- Powell MA, et. al. Gynecol Oncol. 2026:S0090-8258(26)01985-2.
- Mirza MR, et al. N Engl J Med.2023;388(23):2145-2158.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie.Adverse events should also be reported to GlaxoSmithKline on 1800 244 255 or via online form https://gsk.public.reportum.com/.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.
PM-IE-DST-WCNT-260007 | Sept 2026
